GlassScriptPhysician profile
Maureen A Kane
NPI 1386891075
$1,188.34
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.93 · 2022: $496 · 2023: $311 · 2024: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $667.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $465.68 | 2022-2024 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $194.73 | 2022-2023 | |
| Celgene Corporation | $107.81 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $95.97 | 2022-2023 | |
| Novocure INC. | $88.81 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.77 | 2023-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $43.75 | 2023 | Prevymis, Dificid, Zerbaxa |
| Jazz Pharmaceuticals INC. | $27.71 | 2022 | |
| Cti Biopharma Corp. | $25.19 | 2022 | |
| Janssen Biotech, INC. | $24.19 | 2023 | Rybrevant |
| Daiichi Sankyo INC. | $24.11 | 2024 | Vanflyta |
| Incyte Corporation | $23.20 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Kane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.